Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-25
2005-10-25
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000
Reexamination Certificate
active
06958342
ABSTRACT:
Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II:
REFERENCES:
patent: 4382938 (1983-05-01), Kaplan et al.
patent: 4460592 (1984-07-01), Kaplan et al.
patent: 4521422 (1985-06-01), Dusza et al.
patent: 4626538 (1986-12-01), Dusza et al.
patent: 4654347 (1987-03-01), Dusza et al.
patent: 4794185 (1988-12-01), Rossey et al.
patent: 4808594 (1989-02-01), George et al.
patent: 4847256 (1989-07-01), Tseng et al.
patent: 4900836 (1990-02-01), Tomcufcik et al.
patent: 5421422 (1995-06-01), Crane et al.
patent: 5538977 (1996-07-01), Dusza et al.
patent: 5714607 (1998-02-01), Padmanathan
patent: 5891891 (1999-04-01), Benincasa
patent: 6384221 (2002-05-01), Thiele et al.
patent: 6399621 (2002-06-01), Dusza et al.
patent: 6544999 (2003-04-01), Thiele et al.
patent: WO 99/57101 (1999-11-01), None
Brittain, Harry G., (ed.),Polymorphism in Pharmaceutical, Marcel Dekker, Inc., New York, 1999, Chapter 3, “Structural Aspects of Pholmorphism,” pp. 73-124.
Brittain, Harry G., (ed.),Polymorphism in Pharmaceutical, Marcel Dekker, Inc., New York, 1999, Chapter 5, “Generation of Pholmorphs, Hydrates, Solvates, and Amorphous Solids,” pp. 183-226.
Brittain, Harry G., (ed.),Polymorphism in Pharmaceutical, Marcel Dekker, Inc., New York, 1999, Chapter 7, “Effects of Polymorphism and Solid-State Solvation on Solubility and Dissolution Rate,” pp. 279-330.
Cato et al., “Brochure for Clinical Investigators-Sedative Hypnotic Compound CL 285,489,” Cato Research Limited, Study Code 34060-033, Project Report No. 34060-CIB, Apr. 25, 1990.
Foster, “Developments in CNS Drugs II: Drugs of Tomorrow,” Smi Conference, London, UK, May 11-12, 1999.
Niphadkar, “Predevelopment Studies on Sedative/Hypnotic Compound, CL 285,489,” Medical Research Division Formal Laboratory Report, Oct. 3, 1989.
O'Donnell Patrick B.
Thiele William J.
Neurocrine Biosciences Inc.
Seed IP Law Group PLLC
Truong Tamthom N.
Wilson James O.
LandOfFree
Polymorphs of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphs of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3465209